Emergent Biosolutions Inc
Emergent Biosolutions Inc (EBS) Expected Move
EBS expected move through Nov 20, 2026 is 49.1%, with 13 days to expiration. The implied range is $3.18 to $8.93, based on the previous trading day's options prices.
Read more
Tracking the EBS expected move helps you see how far Emergent Biosolutions Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Emergent Biosolutions Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the EBS expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For EBS, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The EBS expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Emergent Biosolutions Inc is unlikely to go.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the EBS expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Emergent Biosolutions Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about EBS.
EBS Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 20, 2026 | 13 | $2.88 | 49.1% | $8.93 | $3.18 |
| Dec 18, 2026 | 41 | $1.48 | 25.2% | $7.54 | $4.58 |
| Jan 15, 2027 | 69 | $1.56 | 26.7% | $7.62 | $4.50 |
| Mar 19, 2027 | 132 | $2.43 | 41.5% | $8.49 | $3.64 |
As of Nov 5, 2026